In an early test of two bispecific T cell engagers combined in a solid tumor, Immunocore said an estimated 70% ...
Satellos changes Duchenne trial endpoint to MRI fat fraction for forazapadin; Amgen's Repatha beats Zetia; MetaVia's DA-1726 ...
Oxford spinout Alethio raises $90M Series A co-led by Sofinnova and RA Capital to take ET antibody ATX-011 into the clinic.
AAFP CEO Shawn Martin plans to push Congress to codify ACIP’s funding and structure, limiting HHS power after RFK Jr.’s ...
Ellipsis, which uses voice AI to screen and chat with patients, bought Kouper Health, which carries out ...
RevMed's Rasonque nets $198M; Madrigal sued over Rezdiffra data; Rezera eyes $181M IPO; ANI bids $560M for Egetis; Cloudbreak ...
Emily Chaddock survived severe preeclampsia at 27 weeks; daughter Mia born under 2 lbs. No drugs exist to prevent it. Eli ...
Endpoints’ Drew Armstrong and Max Bayer join policy expert Nick Shipley live Wednesday to break down what the US midterms ...
Sanofi drops SAR448272, a STAT6 degrader developed with Nurix Therapeutics, after Phase 1 discontinuation. Nurix shares fell ...
Kamau Therapeutics shares early data on nula-cel 2.0 for sickle cell disease; 3 patients show no pain crises or transfusion ...
Pfizer CEO Albert Bourla says Trump’s MFN pricing deals will hold through the end of the term, even if Democrats win Congress.
Biotech pessimism about China more than doubles in Q3 BPSI, making it biopharma’s No. 2 worry, while Big Pharma stays net ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results